# Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

> **NCT02819518** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 882 (actual)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Normale Saline Solution

## Key facts

- **NCT ID:** NCT02819518
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-27
- **Primary completion:** 2021-06-15
- **Final completion:** 2023-10-30
- **Target enrollment:** 882 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819518, "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02819518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*